The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Frank G.A.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

Andreeva Yu.Yu.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Vinogradov I.Iu.

GUZ "Riazanskiĭ oblastnoĭ klinicheskiĭ onkologicheskiĭ dispanser"

Glatko S.B.

GBUZ "Omskiĭ klinicheskiĭ onkologicheskiĭ dispanser"

Gorelik M.Z.

GBUZ "Primorskoe kraevoe patologoanatomicheskoe biuro", Vladivostok

Zavalishina L.É.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Leenman E.E.

FGBU "Rossiĭskiĭ nauchnyĭ tsentr radiologii i khirurgicheskikh tekhnologiĭ" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Matsionis A.É.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

Petrov S.V.

North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia, Elizabethan hospital, Saint-Petersburg, Russia

Sazonov S.V.

GBUZ SO "Institut meditsinskikh kletochnykh tekhnologiĭ", Ekaterinburg

10 years of testing of the HER2 status in breast cancer in Russia

Authors:

Frank G.A., Andreeva Yu.Yu., Vinogradov I.Iu., Glatko S.B., Gorelik M.Z., Zavalishina L.É., Leenman E.E., Matsionis A.É., Petrov S.V., Sazonov S.V.

More about the authors

Read: 2005 times


To cite this article:

Frank GA, Andreeva YuYu, Vinogradov IIu, et al. 10 years of testing of the HER2 status in breast cancer in Russia. Russian Journal of Archive of Pathology. 2012;74(5):3‑6. (In Russ.)

Recommended articles:
Quality control of immu­nohistochemical studies: compulsory duty or urgent need?. Russian Journal of Archive of Pathology. 2025;(2):43-52
Soli­tary fibrous tumor of the kidney. Russian Journal of Archive of Pathology. 2025;(3):77-81

References:

  1. Gershtein E.S., Kushlinskii N.E. Tkanevye markery kak faktory prognozov pri rake molochnoi zhelezy. Prakticheskaya onkologiya. 2002; 3 (1): 38-44.
  2. Zavalishina L.E., Andreeva Yu.Yu., Ryazantseva A.A., Frank G.A. Metodicheskie rekomendatsii po provedeniyu HER2-testirovaniya raka molochnoi zhelezy. Arkhiv patologii. 2011; Prilozhenie.
  3. Zavalishina L.E., Frank G.A. Morfologicheskoe issledovanie HER2-statusa raka molochnoi zhelezy. M.: Media Medica; 2010.
  4. Frank G.A., red. Rukovodstvo po interpretatsii HER2-statusa metodom in situ-gibridizatsii Ventana INFORM HER2 Dual ISH DNA Probe Cocktail Assay. M.: Rosh Diagnostika Rus; 2011.
  5. Slamon D.J., Godolphin W., Yones I.A., Holt J.A., Wong S.G., Keith D.E. et al. Studies of HER2/neu protooncogene in human breast cancer and ovarian cancer. Science. 1989; 244: 707-12.
  6. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER-2. N. Engl. J. Med. 2001; 344 (11): 783-92.
  7. Wolf A.S., Hammond M.E.H., Schwatz J.N., Hagerty K.L., Allred D.C., Cote R.J. American Society of Clinical Oncology / College of American Pathologist guideline recommendations for human epidermal growth receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007; 131 (1): 18-43.
  8. Yaziji H., Goldstein L.C., Barry T.S., Werling R., Hwang H., Elis G.K. et al. HER2 testing in breast cancer using parallel tissue based methods. J. A. M. A. 2004; 291: 1972-7.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.